Sign inJoin waitlistJoin the waitlist

Siqing Fu

Professor · University of Texas M D Anderson Cancer Center

Credentials: · · · · ·

History

University of Texas M D Anderson Cancer Center
Present

Hematology and Medical Oncology
University of Rochester Medicine
2001–2004
Internal Medicine
University of Rochester Medicine
1999–2001
Yale New Haven Hospital - Saint Raphael Campus
1998–1999
Yale Univ Sch of Med
1996–1998
Doctor of Medicine
1981–1985

Research

Genetic marking shows that Ph+ cells present in autologous transplants of chronic myelogenous leukemia (CML) contribute to relapse after autologous bone marrow in CML
Blood · 1994 · 460 citations
Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative
Clinical Cancer Research · 2012 · 452 citations
PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations
Journal of Clinical Oncology · 2012 · 399 citations

David Hong
189 papers
Aung Naing
179 papers
Sarina Piha-Paul
148 papers
Apostolia Tsimberidou
146 papers
FJ
Filip Janku
116 papers
Razelle Kurzrock
110 papers
Funda Meric-Bernstam
103 papers
JW
Jennifer Wheler
91 papers
Vivek Subbiah
91 papers
GF
Gerald Falchook
87 papers
DK
Daniel Karp
74 papers
RZ
Ralph Zinner
43 papers

Clinical trials

Phase Ib Study of CBP-1019 in Combination With FOLFOX +/- Bevacizumab, Pembrolizumab, or Enzalutamide for Metastatic TRPV6-overexpressing Solid Tumors of Epithelial Origin
Principal investigator · Recruiting · Phase 1
M.D. Anderson Cancer Center
2024–2029
Study of VG2025 Delivered Intraperitoneally in Patients With Advanced Solid Tumors With Carcinomatosis
Principal investigator · Withdrawn · Phase 1
M.D. Anderson Cancer Center
2024
Phase I Study of ZN-c3 and Bevacizumab ± Pembrolizumab in Metastatic CCNE1 Amplified and TP53 Mutant Solid Tumors
Principal investigator · Withdrawn · Phase 1
M.D. Anderson Cancer Center
2022
Phase I Study of TSN084 in Patients With Advanced Malignant Tumors.
Principal investigator · Unknown · Phase 1
Tyligand Bioscience (Shanghai) Limited
2022–2025